Amanta Healthcare India IPO is scheduled to be listed on September 9, 2025. According to grey market trends, the shares are trading at a small premium. The listing at BSE and NSE is eagerly awaited by investors.

Amanta Healthcare IPO Listing Date in Focus

The pharmaceutical sector of India is one the biggest sources of investor interest. As Amanta Healthcare‘s IPO is ready to take off on September 9, 2025, the firm has seen her shares being subscribed to with colorful scoops from its retail and institutional investors. The general perception that prevails is that the company is on a strong and bright path.

On BSE and NSE, the IPO listing will be simultaneous thus, witnessing another milestone for the company and co-owners. Wall Street speculators are currently discerning the grey market trend that indicates a small premium which, thusly, guarantees a measured positive reaction to the arrival of the shares.

Strong IPO Subscription Highlights

The subscription for Amanta Healthcare’s IPO was made public from September 1 to 3, 2025, with the allotment being confirmed on September 4. The price split for the IPO was pegged at ₹120-₹126 per share, thereby enabling the company to collect ₹126 crore by issuing 1 crore equity shares subsidiary fresh.

On the stock exchange, the IPO was 82.61 times oversubscribed in total as per BSE data. Retail investors were responsible for a 54.98 times subscription of the total while non-institutional investors (NIIs) were very active and drove the subscription to the maximum at 209.42 times. Qualified institutional buyers (QIBs) were good partners in the project as they committed 35.86 times.

Beeline Capital Advisors Pvt. Ltd. was the book-running lead manager, MUFG Intime India Pvt. Ltd. acted as the IPO registrar.

Also Read: SEBI IPO Approvals: 13 Companies Including Urban Co

Grey Market Premium Signals

The grey market premium (GMP) of Amanta Healthcare IPO shares before the listing indicates a subdued trend. At present, the GMP is ₹9 per share, implying a tentative listing price of ₹135, which is 7.14% higher than the issue price.

Market watchers say that this moderate GMP is good for a balanced sentiment. On the one hand, the need is still quite healthy, on the other hand, the investors seem to be very cautious in line with the current market situation and sector-specific issues in India’s pharmaceutical industry.

Market Implications and Investor Insight

The listing of the Amanta Healthcare IPO has taken the big spotlight in front of retail and institutional investors downstairs in India. In essence, a relatively low GMP suggests a stock market that is likely to open only slightly above the issue price and at the same time very limited gains within a short period will be possible.

The financial world notes that the IPO success will largely be decided by the demand for the shares after the stock market listing and the overall market sentiment. The pharmaceutical sector in India which has been the primary source of domestic healthcare needs has escalated the exports of India to other countries as well, thus creating excellent opportunities for long-term growth which consequently supports optimism.

The listing is believed to have a positive effect on the stock market as the liquidity of shareholding will expand and more stakeholders will be able to actively engage in the firm’s progression.

Potential Growth Drivers

The company Amanta is aligned with a solid strategy in the Indian pharmaceutical market and has its attention fixed on those segments of the medicine that are most required by the market. The company’s approach to doing business and its market coverage, therefore, are predicted to become the keys to increasing profits over the next few years.

Key factors likely to influence the IPO’s performance include:

• Market expansion of pharmaceutical products in India and worldwide.

• Investor demand has been strong, as reflected in high subscription numbers.

• The grey market’s current sentiment is somewhat positive, as also can be seen from the prices.

• Government laws and regulation support related to the domestic pharmaceutical sector.

• Operational expansion and strategic product portfolio development.

FAQ’s

READ MORE ON

Read the full article here: Amanta Healthcare IPO: 5 Key Trends — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

In a move to raise around ₹1,900 crore from the market, Urban Company has fixed its IPO price band between ₹ 98 and ₹ 103 per share. The company will raise funds through a combination of a new issue and an offer for sale. The issue will hit the market on September 10 and close on September 12.

Urban Company Limited is the leading Indian on-demand home and personal services full-stack marketplace, based in Gurugram, Haryana. It is a hardware-software services provider working in the consumer services sector powered by technology and offering the services of home maintenance, cleaning, pest control, plumbing, electrical works, appliance repair, and the beauty & wellness spheres.

Not only in India but also in 51 cities across the globe such as Singapore, and UAE, Urban Company is revolutionizing the way people repair their homes by rapidly expanding the footprint of its reliable digital-first platform, which is by far the easiest way to access quality and convenience at the right scale and time.

Urban Company IPO Price Band Announcement

Based on a disclosure to the exchange, Urban Company has decided the IPO price band per share to be in the range of ₹98 to ₹103. The IPO will start on Sunday, September 10, 2025, and will come to an end on Tuesday, September 12, 2025.

The company aims to raise around ₹1,900 crore if the issue is priced at the higher end of the price band. The total issue comprises a fresh issue of ₹472 crores and an offer-for-sale (OFS) of ₹1,428 crores.

IPO Details and Lot Size

Investors willing to take part in the upcoming Urban Company IPO (Initial Public Offering) are required to apply for a minimum of 145 shares, i.e. one lot, or in multiples thereof. Based on the price band, a retail investor will require at least ₹14,935 to subscribe to one lot.

Also Read: Urban Company Posts ₹239 Cr Profit, Prepares for Blockbuster ₹1,900 Cr IPO

The quota division for capital issues is given below:

• QIBs, or Qualified Institutional Buyers, will have a 75% allotment.

• Non-Institutional Investors (NIIs) get 15% of the priority sector quota.

• Retail investors are allotted 10 percent of the shares.

• Moreover, employees of the company meeting the necessary conditions will be allotted shares amounting to ₹2.5 crore.

The anchor book will be open on September 9, 2025, which is a day before the IPO.

Use of Funds Raised Through IPO

Urban Company has specified how the money from the new issue will be spent:

• ₹190 crore of the money will be allocated towards new technology and cloud infrastructure investments.

• ₹75 crore will go towards the payment of office space leases.

• ₹90 crore will be allocated towards advertising and brand building.

• The remainder will be used for general corporate purposes such as to invigorate the company’s balance sheet and support long-term growth.

These disbursements reflect the company’s plans to expand its operational scale, uplift the customer experience, and accelerate its digital transformation.

Urban Company IPO Price Band in Market Context

The news of the Urban Company IPO price band has excited the financial markets a lot. On the Indian stock exchanges, consumer-facing technology companies are currently in vogue, which makes this offering even more attractive.

Urban Company not only with its strong brand recall but also with its ever-growing customer base and diversified service portfolio is on the verge of turning this IPO into one of the most brilliant mainboard listings of 2025.

The level of interest in the offerings within the institutional and retail categories is being closely checked by market players, as the IPO is expected to be a true test of investor willingness to buy platform-based service models in India.

Business Model and Growth Potential

Urban Company’s business model centers around:

• Technology-first approach – making a booking of a service and delivery of the service operating smoothly via the web or mobile app.

• Professional partnerships – In this, the company is taking care of the tech and the marketing and is training and equipping independent professionals through user-friendly digital tools and offering easier access to credit.

• Customer convenience – Providing home and personal care categories services from start to finish.

The company will be able to take off successfully with the help of increasing urbanization, the rise in dual-income households, and the digital trend with people opting for e-services and with the way things are going Urban Company is really poised to take not only long term but huge growth opportunities both in India and abroad.

Grey Market Premium (GMP)

Currently, the Urban Company IPO GMP (grey market premium) stands at ₹10 per share which is the last time this figure was mentioned, indicating that the stock in the unofficial market is being sold at a premium of ₹10 per share over its issue price.

Also Read: Urban Company Secures ₹450 Crore Pre-IPO Funding from SBI Mutual Fund and Permira

The GMP is not an official gauge of the stock’s future performance, however, it represents investors expectations and their sentiments with regard to listing gains in the near term.

Why the Urban Company IPO Price Band Matters

It is crucial for investors, as they are looking for the right time to enter the market, to know that setting the Urban Company IPO price band between ₹98 and ₹103 per share was a wise decision. The aims of a balanced price range are:

• Ensure efficient institutional subscription.

• Allow retail investors the possibility of making a small investment along the way without compromising the buy-in price.

• Enable a smooth aftermarket performance with the stock price staying stable.

For them it is the question of betting on the growth that the Indian mobile sector is going to have in the future world and thus making a wise decision infused with great technological insight.

Outlook and Long-Term Strategy

The company’s future development plan is based on:

Bringing more possibilities to service categories in home and personal care areas.

Working on the company’s tech infrastructure (such as creating apps, websites, or customer service support) so that more customers can use services provided by the company.

Devoting the necessary resources to the education of the professionals who deliver the product or service with the goal of ensuring consistency and dependability.

Operating overseas in a way of locating rapid in-flow of customers and targeting countries with a vast potential for expansion of the company’s on the ground.

The company will utilize the funds it is to acquire through its IPO to amplify its competitive advantage by being more versatile, increasing scalability, and attracting long-term shareholder value.

Key Takeaways

The designation of the Urban Company IPO price band is a noteworthy landmark on the company’s path as it moves into the public domain. With an e-commerce platform that is top-notch in tech, a plethora of services, and expansion dreams that only the sky limits, Urban Company plans to make professionals the consumers when it comes to India as well as the rest of the planet.

Although whether the public offering will go well in the short run will be up to market sentiment, the IPO role players will still carry the torch and be part of the bright future that will be witnessed in one of India’s leading marketplaces in the tech-enabled and service-based sector.

FAQ’s

READ MORE ON

Read the full article here: Urban Company IPO Price Band Fixed at ₹98-103 — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Anlon Healthcare IPO allotment date is expected to be on September 1, 2025, with a scheduled listing on both BSE and NSE, on September 3. The investors can check the allotment status online by going through the websites of BSE, NSE, or Kfin Technologies.

Located in Mumbai, Maharashtra, Anlon Healthcare Limited is a chemical company that deals with the production of pharmaceutical intermediates and fine chemicals. The company offers the healthcare and chemical industries several high-quality solutions through the segments of drug development and specialty chemicals, besides other related services.

Nevertheless, the company has had a successful flotation in the primary market, which attracted notable investor interest although the secondary market environment is quite challenging. The fresh issuance of equity shares in the public issue grants Anlon Healthcare the avenue for raising funds for expansion, meeting working capital needs, and consolidating the company’s financial position.

IPO Subscription and Fundraising

The Anlon Healthcare IPO was a subscription open from August 26 to August 29, 2025, with the price bracket of ₹86–₹91 per share. The book-building issue had effectively raised ₹121.03 crores by offering 13.3 million equity shares.

The IPO left no stone unturned and gained a subscription of 7.13 times in aggregate, which is indicative of the serious demand for this kind of issue cutting across the investor categories:

• Retail Individual Investors (RIIs): Subscribed 47.30 times

• Non-Institutional Investors (NIIs): Subscribed 10.61 times

• Qualified Institutional Buyers (QIBs): Subscribed 1.07 times

The positive sign is the robust subscription that resonates with Anlon Healthcare’s expansion plans and its focus on specialty chemicals and healthcare manufacturing sectors.

Anlon Healthcare IPO Allotment Date

The company has decided the tentative IPO allotment date to be September 1, 2025. After the allotment is finalized, the shares will be credited to the demat accounts of lucky investors on September 2, 2025. However, on the same day, refunds will be issued to the unsuccessful applicants.

Anlon Healthcare’s IPO listing date, on the other hand, is expected to be on September 3, 2025, with the shares debuting on both the BSE and the NSE.

Grey Market Premium (GMP)

As of now, Anlon Healthcare shares are being traded at a low grey market premium (GMP) of ₹2 per share over the issue price of ₹91, which indicates an expected listing price of about ₹93, or a 2.2% premium. Although GMP trends are one of the tools that investors rely on to forecast listing prices, the actual market performance will depend on the forces of supply and demand on the listing day.

Also Read: Everything You Need to Know About Anlon Healthcare’s Upcoming IPO

How to Check Anlon Healthcare IPO Allotment Status

By using the BSE, NSE, and the Kfin Technologies registrar online platforms, investors are in a position to check their allotment status of the Anlon Healthcare IPO.

On BSE Website

• Go to the BSE IPO Allotment Page

• Select “Equity” as the Issue Type

• Choose “Anlon Healthcare Limited” from the drop-down

• Type in your Application Number or PAN

• After entering the details, verify the captcha and click on the Search button

On NSE Website

• Navigate to the NSE IPO Status Page

• Tick “Equity and SME IPO bids”

• Pick “Anlon Healthcare Limited”

• Write PAN and Application Number

• Click Submit to show status

On Kfin Technologies Website

• Go to the Kfin IPO Status Portal

• Select “Anlon Healthcare Limited” from the dropdown

• Fill in Application Number, Demat Account, or PAN

• Enter Captcha and click Submit

The details of the allotment will be provided instantly on the respective portal.

Expected Listing Impact

The investing community will be closely monitoring the IPO listing on September 3, 2025. The debut of Anlon Healthcare is likely to be very attractive to the healthcare and chemical stock sectors given the high subscription, especially from retail investors.

The company’s stable financial performance, along with its involvement in the rapidly growing pharmaceutical intermediates market, makes it a good candidate for sustained growth. However, short-term listing profits might be limited, due to the low GMP.

Also Read: Anlon Healthcare IPO Day 1

Key Takeaways for Investors

• IPO Allotment Date: September 1, 2025

• Demat Credit & Refunds: September 2, 2025

• IPO Listing Date: September 3, 2025 (BSE & NSE)

• Amount Raised: ₹121.03 crore

• Subscription: 7.13 times overall

• Price Band: ₹86–₹91 per share

• GMP Today: ₹2 premium per share

Anlon Healthcare IPO Allotment Update

The Anlon Healthcare IPO allotment is the result that the investors look forward to after the issue subscription. As the credit of shares is expected in the near future, it is a good idea for the applicants to look at their allotment status without any delay on BSE, NSE, or Kfin Technologies.

The market reaction to the imminent IPO listing on September 3 will be the main focus, although the signal of investor enthusiasm is the vigorous retail subscription. While awaiting the Anlon Healthcare IPO allotment, the market players are eagerly awaiting for the instant listing profits and long-run investment possibilities.

FAQ’s

READ MORE ON

Read the full article here: Anlon Healthcare IPO Allotment Date, Status, Listing Update — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Amanta Healthcare, a pharmaceutical manufacturer, is scheduled to inaugurate its ₹126 crore IPO on September 1, through an offer of 1 crore fresher equity shares. The public offering plans to have more funds allocated for facility expansion and to strengthen the company’s manufacturing capacity.

Amanta Healthcare Limited, a pharmaceutical company from Ahmedabad, Gujarat, offers sterile liquid products and medical devices as its specialty. The company was established in 1994 and has been successful in packaging technology of the future like Aseptic Blow-Fill-Sepal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company has been growing steadily and is well-known as it can provide healthcare products to both the Indian and foreign markets.

The company’s new Initial Public Offering (IPO) is a landmark moment in its 30-year history and signifies a step closer to its goal of increasing production and extending the range of products available in the healthcare sector.

Amanta Healthcare IPO: Size and Structure

Amanta Healthcare’s IPO will open for subscription on September 1, 2025 and will be available till September 3, 2025.

The ₹126 crore mainboard initial public offering (IPO) is entirely a fresh 1 crore shares equity release. There is no offer-for-sale (OFS) component, which means that the company will directly use the money raised for cash flow rather than promoter holdings be diluted.

This design clearly indicates that the company is not looking for the money but instead wants to focus on growth and development, hence, providing the investors an opportunity to access the next phase of expansion in the company.

Amanta Healthcare IPO: Price Band and Lot Size

The IPO price range has been set between ₹120 and ₹126 per share.

For retail investors:

• Minimum application: 119 shares

• Investment value: At the upper price band, ₹14,994

For non-institutional investors (NIIs):

• Small NII: About Rs 2.1 lakh minimum investment

• Big NII: About Rs 10 lakh minimum investment

The allocation makes it possible for as many people as possible to take part in it while keeping the entry point simple for retail investors, which is a crucial point for investor relations.

Also Read: Amanta Healthcare IPO Opens: Gujarat Pharma Firm Targets ₹126 Crore Raise

Amanta Healthcare IPO: Important Dates

Investors should remember the following key dates in the IPO schedule:

• IPO Opens: September 1, 2025

• IPO Closes: September 3, 2025

• Basis of Allotment: September 4, 2025

• Listing Date: September 9, 2025 (NSE & BSE)

The dual listing on the two big exchanges is beneficial as it provides wider accessibility to liquidity and better visibility for both institutional and retail investors.

Use of Proceeds: Funding Expansion

As per the information contained in the company’s Red Herring Prospectus (RHP), the money raised through the IPO is expected to be mainly utilized for the expansion of the Hariyala unit in Kheda, Gujarat.

• Almost 70% of the money will be directed towards the construction of a new building and the purchase of equipment for the SteriPort manufacturing line.

• The rest of the 30% will be used to the SVP line to increase the production capacity of the sterile liquid product portfolio.

• A smaller part of the company’s general corporate purposes will be used to increase its financial flexibility.

This facility expansion plans to back Amanta’s strategy of catering the increasing need for the pharmaceutical market in the country and abroad.

Amanta Healthcare IPO: Valuation Metrics

If the issue is priced at the upper end of the band, i.e., ₹126, a post-money market cap of around ₹489 crore is envisaged for the company.

The corresponding Price-to-Earnings (P/E) ratio is 46.6x, indicating a fair amount of trust in the company’s growth potential by the investors. When compared to listed peers in the pharmaceutical sector, the valuation trend shows that it sits at the middle of the range with a slight premium, justified by Amanta’s niche product portfolio and the company’s growth prospects driven by the expansion.

Amanta Healthcare IPO: Business Fundamentals

 Amanta Healthcare’s competitive advantages are as follows:

• Targeted production: the production of sterile liquids and parenterals is the main focus; these are products that require sophisticated technology and are subject to regulatory procedures.

• Highly reliable tech: the use of ABFS and ISBM technologies allows for the utmost quality of packaging, which is fundamental for guaranteeing the integrity of the pharmaceutical products.

• Varied Portfolio: the company’s activities cover not only drugs but also medical devices, thus the firm is less exposed to the risk of the pharma vertical.

• Business Expansion Paths: there are plans for an increase in capacity and turnover due to the new projects in Gujarat plants.

These essentials fit the trend of the long-term drivers of sectoral growth such as the rising demand for health services, increased hospital infrastructure, and India’s position as a global pharmaceutical hub.

FAQ’s

READ MORE ON

Read the full article here: Amanta Healthcare IPO Opens Sept 1: Key Issue Details — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Open interest in Vikran Engineering IPO has been phenomenal as by the third day of submissions, the total subscriptions had crossed 7 times. Trading in the grey market is steady and as the expiry date is close, there are no surprises on the issue’s closing date.

Vikran Engineering IPO Day 3 Subscription Update

Mumbai’s Vikran Engineering Limited is carrying out activities in the engineering, procurement, and construction (EPC) area. By their asset-light business model, the company has become a one-stop shop for the clients for all their needs, regardless of whether it is power transmission, water, or railways sector, and irrespective of the project scale/size.

Positive Trend of IPO and Encouraging Participation of the Public

The issue of the Vikran Engineering IPO started the Indian primary market on Tuesday, August 26, 2025, and will be available for subscription until Friday, August 29, 2025. By the third day of bidding, the issue reflected strong investor enthusiasm, particularly in the retail and non-institutional investor categories.

At 11:03 AM on Day 3, the subscription overall reached 7.23 times. The investors from the retail segment invested Rs.6.58 crore that corresponds to the level of 6.58 times, whereas the non-institutional investor (NII) segment surged to 17.13 times. The qualified institutional buyer (QIB) segment, however, posted a relatively small amount of 0.94 times of the subscription at that particular time.

Grey Market Premium (GMP) Trend

The Vikran Engineering IPO grey market premium (GMP) was at ₹13 per share without any change from Day 2, but a bit lower compared to the previous day when it was ₹14. Even with wider market volatility and selling pressure in the Indian equities market, the GMP is still showing steady support for the IPO. Grey market movements can be one of the leading signals of listing expectations and the stable GMP for Vikran Engineering suggests that strong demand from investors before the stock market debut is the correct call.

Key IPO Details

• Issue Closing Date: August 29, 2025

• Probable Allotment Date: August 30, 2025 (or September 1, 2025, in case of a delay)

• Expected Listing Date: September 3, 2025

• Price Band: ₹—₹97 per share (upper band valuation)

Also Read: Vikran Engineering IPO Opens Today: Subscription Window and Key Highlights Explained

Valuation Range: The problem is designed to be a price-to-earnings (P/E) ratio of approximately 22x-32x for FY25 with peers in the same sector, thus making a competitive issue.

Sectoral Advantage and Growth Drivers

Vikran Engineering has broad its presence in several infrastructure verticals such as:

• Power Transmission: Helping the modernization of the grid in India and the incorporation of renewable energy.

• Water Infrastructure: Being the major contributor to large-scale public projects such as the Jal Jeevan Mission which aims to provide tap water connections to households.

• Railways: Doing the work of track electrification, signaling, and other EPC contracts that are allied.

Also Read: Vikran Engineering Gears Up for ₹772 Crore IPO with Strong Infrastructure Portfolio

The infrastructure boom in India, which is mainly supported by government schemes like the Revamped Distribution Sector Scheme (RDSS) and the continuous investments in water supply and rail networks, is a very good opportunity for EPC players like Vikran Engineering.

What Investors Should Watch

The Vikran Engineering IPO has attracted significant market traction due to robust retail and NII participation, coupled with sustained GMP levels. The investor’s interest indicates the company’s diversified order book, asset-light model, and the capability to utilize infrastructure growth in India as the reasons for their trust. The occurrence of the allotment and listing dates will be very important events for the participants who have been tracking the debut performance of the stock.

FAQ’s

READ MORE ON

Read the full article here: Vikran Engineering IPO Day 3 Subscription Update — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Anlon Healthcare’s ₹121 crore IPO was 1.69x overall subscribed on Day 1 with a robust retail bid, whereas institutional interest and GMP patterns remained subdued.

Anlon Healthcare IPO Day 1

India’s primary market witnessed fresh activity when Anlon Healthcare got off with a ₹121 crore IPO on August 26, 2025, drawing good attention from retail investors on its opening day. The overall subscription touched 1.69 times while the grey market premium (GMP) stayed flat at ₹5, indicating only moderate listing expectations despite a retail frenzy.

Day 1 Subscription Snapshot

At the end of the first day, the IPO showed 1.69x overall subscription. Retail investors took the initiative with their quota being oversubscribed 8.99 times, whereas institutional demand was rather weak (QIBs at 0.91x and NIIs at 0.71x).

The subdued GMP of ₹5, or a 5.49% premium, outlines a cautious approach towards short-term listing gains. Analysts say that the call subscription momentum will become obvious as they reach the final day, upon which institutional investors will make their moves.

Anlon Healthcare is the manufacturer of pharmaceutical intermediates and active ingredients (APIs) needed for drug production. The company does not sell finished medicines but instead provides the necessary building blocks for tablets, capsules, syrups, skincare products, nutraceuticals, and veterinary health solutions.

As of March 31, 2025, Anlon had 65 commercial products, 28 at the pilot stage, and 49 under development. Besides that, it also does custom chemical manufacturing and helps pharma companies with the regulatory filings for their global exports.

Use of IPO Proceeds

The company will direct the money to capacity expansion, debt repayment, and working capital:

• ₹30.72 crore – Expansion of the plant with a capacity of 700 MTPA (current 400 MTPA).
• ₹5 crore – Debt repayment.
• ₹43.15 crore – Working capital for the purchase of raw materials and for the daily activities of the company.
• Balance – For general corporate purposes.

Financial Strengths

• Profits skyrocketed almost 4x in two years: from ₹5.8 crore (FY23) to ₹20.5 crore (FY25).
• The debt-to-equity ratio was reduced dramatically from 9x to 0.73x.
• Customer satisfaction with 33 audits in FY25 and no cancellations of orders.
• DMF certifications in Brazil, China, and Japan have removed barriers to global markets.

Key Risks

• The sales dropped from ₹113 crore in FY24 to ₹67 crore, reflecting revenue instability.
• The top 10 customers (77.7% of the revenue) are the major source of the company’s revenue—there is always a risk of high concentration.
• The single manufacturing plant in Rajkot that produces the goods exposes the company to operational risks.
• The long working capital cycle (308 days) is putting a lot of pressure on the company’s cash flows.
• The heavy dependence on suppliers—90% of raw materials come from only 10 vendors.

Peer Comparison

At the upper price band, Anlon’s P/E of 14.3x looks attractive relative to its listed peers.

By buying Anlon Healthcare, investors can enter a market that is growing very fast and the asking price is quite reasonable. The positive aspects are made up by profit, margin increase, and low debt. However, the company’s risks being the small scale, the dependence on major customers and the instability of sales.

Retail enthusiasm is evidenced by almost a 9x subscription, but institutional hesitancy and an unchanged GMP indicate a cautious outlook for listing. Long-term investors with a high-risk profile may find it attractive, while conservative ones may prefer to wait for the final subscription data or the listing performance.

FAQ’s

READ MORE ON

Read the full article here: Anlon Healthcare IPO Day 1 — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Shreeji Shipping made its stock market debut with an 8% premium on the BSE but slipped to near its IPO price by closing. Despite strong investor demand, the listing premium was below grey market expectations.

Shreeji Shipping IPO Debut

Headquartered in Gujarat, India, Shreeji Shipping and Logistics Limited is a company that provides services in the shipping and logistics sector and is an end-to-end transporter of dry bulk cargo along with the supply of the integrated logistics solution. They have established a strong footing in the rising logistics industry of India where they are serving the trade route both at home and abroad.

On August 26, 2025, their shares were introduced on the Bombay Stock Exchange (BSE) at ₹271.85 per share which was a 8% premium to the IPO price of ₹252 per share. Nevertheless, the very first session witnessed a turnaround as the stock went down more than 6%, and finally, it closed at ₹254.60 per share, marking a mere 1% increase over the issue price. 

Comparatively, on the National Stock Exchange (NSE), the shares were released at ₹270 per share implying a 7% premium but the closing was at a lower value of ₹254.40 per share. Total market capitalization of the company was about ₹4,148 crore at the close of the day.

IPO Subscription and Market Response

The ₹411-crore of Shreeji Shipping IPO, held between August 19–21, received a robust investor response. The issue was subscribed over 58 times, reflecting significant investor appetite.

The entire issue comprised a fresh share offering, priced in the band of ₹240–₹252 per share. Investors were required to apply for a minimum lot of 58 shares, translating to an investment of ₹14,616 at the upper band.

Also Read: Shreeji Shipping Global IPO Opens on August 19

While the company managed a positive listing, the premium was lower than grey market expectations. Before listing, unlisted shares traded at a grey market premium (GMP) ranging between 11 — 13.5%, but the actual market debut reflected a modest single-digit gain.

Company Performance and Financial Snapshot

In the financial year 2024, Shreeji Shipping recorded a revenue of ₹736 crore. The top line came down to ₹610 crore in the next fiscal year. However, the company maintained a good profit level which is evident from the 13% increase in net profit to ₹141 crore on a year-on-year basis. The performance uptick was driven by the company’s good cost control and better operational efficiency.

The company’s return ratios remain among the best in the industry:

• Return on Equity (ROE): ~44%
• Return on Capital Employed (ROCE): ~32%

However, the company is still priced at a higher valuation than the average of the sector, with a P/E ratio of approximately 29 and a P/B value of more than 5.

Investor’s perspective

The positive reception of the IPO is a clear signal of the investors’ trust in the logistics transformation narrative in India. This company’s concentration on dry bulk cargo, the utilization of resources to the maximum extent, and the provision of integrated logistics services are the three factors that will ensure the company’s sustainable growth and future prosperity.

Also Read: Shreeji Shipping Global IPO Day 1: GMP, Subscription Status

On the other hand, market experts have identified some issues that may constitute risk factors for the stock:

• Volatility in global freight cycles
• Dependence on dry bulk trade
• High customer concentration

For retail investors and institutions, Shreeji Shipping is a great move, which can give positive results in the short run but also has a triple of the long-term if the shipping business cycles stay positive.

FAQ’s

READ MORE ON

Read the full article here: Shreeji Shipping IPO Debut: Lists at 8% Premium — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Here, we are talking about the Hyderabad based company Ardee Engineering Ltd getting permission from the SEBI to execute a ₹580 crore IPO including ₹500 crore of the fresh issue and ₹80 crore of the promoter’s offer for sale. The company intends to raise the requirements through the issue to complete the requirements of manufacturing expansion both in Telangana and Andhra Pradesh, discharge of borrowings and meet the requirements of corporate. 

Locally, in Hyderabad, Ardee Engineering Limited, Telangana, functions as an engineering solutions provider focusing on pre-engineered buildings, electro-mechanical projects, and civil works. The brand was initially engaged in infrastructure and industrial projects, but now it offers vertical integration in multiple engineering domains. 

Ardee Engineering has established the expertise to undertake large projects for the expansion of the company all over India where they have their operations. Their major clients are in the construction, manufacturing, and engineering services sectors. The firm competes with several listed peers, including Pennar Industries, Everest Industries, Capacite Infraprojects, PSP Projects, Ahluwalia Contracts, and ISGEC Heavy Engineering. 

Ardee Engineering IPO Structure and Details 

The Ardee Engineering IPO has been given a green light by the Securities and Exchange Board of India (SEBI). The scheme tells us that the size of the issue is ₹580 crore which is made up of: 

• Newly issued shares worth ₹500 crores 

• Earlier-promoted Chandra Sekhar Moturu will sell shares amounting to ₹80 crore, thus making the offer-for-sale (OFS) fixed for him. 

The IPO is a follow-up to the Draft Red Herring Prospectus (DRHP) that was filed in March 2025. With SEBI’s observation letter, the company is now authorized to make the issue anytime within the next one year. 

Possible Pre-IPO Placement

Ardee Engineering may also consider a pre-IPO placement of up to ₹100 crore before launching the public issue. If completed, the size of the fresh issue will be adjusted accordingly. Such a move could provide early momentum and strengthen investor confidence in the IPO.

Utilization of Funds 

The company, through its IPO document, has shown how the funds can be deployed: 

• The company will spend ₹279.63 crore to set up two manufacturing units in Seetharampur, Telangana. 

• The company will invest ₹44.84 crore in the establishment of a new integrated manufacturing unit in Parawada, Andhra Pradesh. 

• ₹65 crore will be the part that the company will pay to the lenders thus reducing loans. 

• The rest will be used for general corporate purposes, which are expected to provide the company with the resources necessary for the further expansion of the business activities. 

These expansions are expected to increase Ardee Engineering’s manufacturing capacity and position it well to tap into the rising demand in pre-engineered building solutions and infrastructure-related engineering works. 

Market Position and Industry Outlook 

The sector of engineering and infrastructure solution in India is successfully developing with the support of the industrial construction, smart cities, and infrastructure modernization projects. Ardee Engineering is one of the companies that offers the best solutions to the trend by implementing structural designs and executing a project as an integrated whole. 

Ardee Engineering plans to strengthen its balance sheet and improve profitability in the long run by increasing its production capacity and reducing its debts. The IPO proceeds are expected to serve as a form of financial flexibility and operational robustness laying in a company’s growth strategy. 

Lead Managers

IIFL Capital Services and JM Financial, the two entities that have been selected as book running lead managers, are said to be the head authorities of the IPO. They, among their various duties, will be responsible for managing the offer, ensuring that all the rules and regulations are followed, and guiding the listing process to have a hassle-free flow.

Road Ahead 

With the approval of SEBI, Ardee Engineering is preparing to go public, thus joining the long list of companies that have resorted to equity markets to raise expansion capital. This IPO is a significant step towards the company’s plans to deepen its manufacturing base and raise its competitiveness in the engineering solutions sector. 

The strong project pipeline of the company and its attention to infrastructure growth in India will make the debut eagerly awaited by investors.

FAQ’s

READ MORE ON

Read the full article here: SEBI Approves Ardee Engineering IPO Worth ₹580 Crore — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

Amanta Healthcare, a pharmaceutical manufacturing company from the state of Gujarat has set the price band of its Initial Public Offering between ₹120 and ₹126 per share. The company is willing to collect ₹126 crores to finance new factory projects and improve their product line.

Amanta Healthcare Ltd. is a company from Desa Hariyala, District Kheda, Gujarat, that offers pharmaceutical products. The company commenced operations in 1994 with a healthcare division which included sterile liquid formulations and medical devices. One of their products is IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions and eye lubricating products. The latest technology such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) is used in packaging. Amanta Healthcare has become an international exporter from a local player by establishing its footprint in Africa, Latin America, and the UK.

IPO Structure and Price Band

The company has disclosed its Initial Public Offering (IPO) with a price range from 120 to 126 Rs per share of equity. By issuing 1 crore fresh shares to the public, Amanta Healthcare plans to collect ₹126 crores. Notably, the current issue consists entirely of a fresh issue of shares, so there will not be any selling of shares by the promoters.

As per the Red Herring Prospectus (RHP), the issue structure allocates:

• 50% to Qualified Institutional Buyers (QIBs),
  
• 35% to Retail Individual Investors (RIIs), and
  
• 15% to Non-Institutional Investors (NIIs).
  

IPO Timeline and Allotment Details

The subscription window will be available on Monday, September 1, 2025, and it will be closed on Wednesday, September 3, 2025. The anchor investor allocation is expected to take place on Friday, August 29, 2025.

Basis for allotment: Thursday, September 4, 2025

Expected listing: Monday, September 9, 2025

Stock exchanges: BSE and NSE

The size of the lot has been determined at 119 shares, thus retail investors are required to make a minimum investment of ₹14,994. The maximum bid allowed for retail investors is limited to 13 lots.Use of Proceeds

Funds raised will be channelled towards:

• Civil construction work for expansion at its Hariyala facility in Gujarat,
  
• Purchase of plant and machinery to set up new manufacturing lines for SteriPort and SVP products,
  
• General corporate purposes.
  

Issue Management

The IPO is being managed by Beeline Capital Advisors as the Book Running Lead Manager (BRLM), while MUFG Intime India Pvt Ltd serves as the Registrar of the Issue.

Company’s Growth Potential

Amanta Healthcare has been dealing with the management of fluid therapy and sterile solutions, successfully, for over two decades. The company has been establishing its position in the market without any break. Their dedication to innovation and global quality standards can be seen in their modern production lines and research and development labs.

The IPO that the company will be making in the near future is probably going to be the reason for a subsequent rise in the local and foreign market demands, hence, a deeper penetration of the Indian pharma industry, which is already witnessing a rapid expansion of the pharmaceutical sector.

READ MORE ON

Read the full article here: Amanta Healthcare IPO Opens: Gujarat Pharma Firm Targets ₹126 Crore Raise — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).

On the 26th of August 2025, Vikran Engineering Limited, a company in the Engineering, Procurement, and Construction (EPC) sector, brought in its Initial Public Offering (IPO) with the price band of ₹92-₹97 per share. The company is expecting to collect around ₹772 crores through a mixture of a fresh issue and an offer for sale.

Based in India, Vikran Engineering Limited is a pan-India asset-light business model company that has become a significant player in the EPC sector and is engaged in power transmission, water infrastructure, and railway sectors, among others. Consequently, the company has successfully created a national presence without having to rely on its substantial assets and has been serving the most prominent government and public-sector clients across the country to prove its business philosophy.

Vikran Engineering has structured its IPO case to comprise a fresh issue of 74.33 million equity shares worth ₹721 crore and an offer for sale (OFS) of 5.3 million shares, ₹51 crore by promoter Rakesh Ashok Markhedkar. Hence, the total amount of the problem is ₹772 crores.

On the 25th of August 2025, the company raised ₹232 crore from anchor investors by allotting 23.87 million shares at ₹97 each. The leading institutions such as Bank of India Mutual Fund, Nippon India Mutual Fund, SBI General Insurance, Societe Generale, and360ONE took part in the anchor allotment, indicating early institutional interest signaled.

Grey Market Premium (GMP)

As per the data gathered by market trackers, shares of Vikran Engineering which are not listed in the open market and are being traded in the grey market were said to have a value of ₹118. This means that the stock fetched a premium of ₹21 over the upper band price of ₹97.

Also Read: Vikran Engineering Gears Up for ₹772 Crore IPO with Strong Infrastructure Portfolio

IPO Timeline and Lot Size

• Subscription Window: August 26–29, 2025
  
• Basis of Allotment: September 1, 2025
  
• Listing Date: September 3, 2025, on BSE and NSE
  
• Price Band: ₹92–₹97 per share
  
• Lot Size: 148 shares per lot
  
• Minimum Investment (Retail): ₹14,356 at the upper price band
  
• Maximum Retail Investment: 13 lots (1,924 shares) worth ₹1,86,628
  

Fund Utilisation

As per the Red Herring Prospectus (RHP), proceeds from the fresh issue will be directed towards:

• Meeting working capital requirements
  
• Supporting general corporate purposes
  

Lead Managers and Registrar

The issue is being managed by Pantomath Capital Advisors and Systematix Corporate Services as book-running lead managers, while Bigshare Services is the registrar to the issue.

READ MORE ON

Read the full article here: Vikran Engineering IPO Opens Today: Subscription Window and Key Highlights Explained — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).